New sleep aid HS-10506 enters final testing phase

NCT ID NCT07587385

Not yet recruiting Symptom relief Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 study tests whether the drug HS-10506 helps Chinese adults with insomnia fall asleep faster and wake up less during the night. About 732 participants will receive either the drug or a placebo for up to 84 days. The study measures sleep using both overnight lab tests and daily sleep diaries.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HS-10506 tablet
What this could lead to: If successful, this could provide a new treatment option for insomnia, helping people fall asleep faster and stay asleep longer.
What could go wrong: This is a phase 3 trial, but results may not apply to all populations. The drug may cause side effects or not work better than placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INSOMNIA DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

insomnia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INSOMNIA DISORDER

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.